The clinical study of the efficacy of two doses of influenza vaccination to the patients with malignancies.
Not Applicable
- Conditions
- Any kind of malignancies
- Registration Number
- JPRN-UMIN000011918
- Lead Sponsor
- Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1>The patients who had fever at the time of vaccination. 2>The patients who had an acute febrile illness at the time of vaccination. 3>The patients known anaphylactic shock to the ingredient of the influenza vaccine. 4>The patients received corticosteroid (0.3mg/kg of prednisone minimum dose.) 5>The patients with platelet count less than 20000/µl. 6>The patients received a live vaccine within 4weeks or inactivating vaccine or toxoid within 1week. 7>The patients treating only with hormonal therapy. 8>The patients whose doctor judge as ineligible
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method We evaluate the efficacy of two doses of influenza vaccine in patients with malignancies receiving chemotherapy. Influenza immunity was defined as HI titre of >40 to all three influenza subtypes after vaccination.
- Secondary Outcome Measures
Name Time Method